Venous thromboembolism is a common cause of morbidity and the single most preventable cause of mortality in hospitalized patients.
Saringer Life Sciences has developed a compact battery-operated venous pump, Venowave, which generates a wave-form motion to prevent a venous thromboembolism (Deep Vein Thrombosis DVT) . When worn firmly on the calf using the adjustable buckles and Velcro straps, the device produces upward volumetric displacement which translates to an increase in venous flow. Based upon patented wave generating technology, the Venowave VW5 weighs less than half a pound and operates by means of a single AA battery.
A new clinical study, conducted at McMaster University with Hamilton Health Sciences 150 patient, phase 11/111 randomized controlled trial is a critical milestone in the development of this new medical technology. The purpose of the validation study was to evaluate the tolerability, efficacy and safety of this new, light-weight, battery-operated compression device for the prevention of venous thrombosis in hospitalized patients. Based on the efficacy results alone, the Venowave device has become an accepted part of clinical practice.
With support of this clinical research and outcome, Venowave will be recommended as an added treatment for the prevention of venous thrombosis in neurosurgical patients and to other high risk categories.